Linkage Biosciences joins Thermo Fisher Scientific's Transplant Diagnostics business, which now represents both the One Lambda™ and Linkage Biosciences brands.
As the leader in HLA for over 30 years, One Lambda has antibody screening assays that can help your lab meet and exceed the new standard.
LABScreen Single Antigen kits are effective tools for detecting HLA antibodies, both pre- and post-transplantation. Now with our expanded coverage kits you have the power to develop even more complete antibody profiles for your patients.
Thermo Fisher Scientific's One Lambda Brand Signs Exclusive Licensing Agreement with Transcriptome Sciences Inc. for access to Molecular Microscope Diagnostic System
CANOGA PARK, Calif., May 16, 2017 (PRNewswire) -- One Lambda, a Thermo Fisher Scientific brand, announced today that it has signed an exclusive licensing agreement with Transcriptome Sciences Inc. (TSI) of Edmonton, Canada for its new microarray biopsy service, the Molecular Microscope™ Diagnostic System (MMDx).
One Lambda Announces the Availability of its New RUO NXType Kit, a Complete Solution for HLA Typing by NGS
CANOGA PARK, Calif.--(BUSINESS WIRE)--One Lambda, Inc., part of Thermo Fisher Scientific and leading producer of research and in vitro diagnostic products for the HLA transplant community, today launched its RUO NXType™ Kit, a research use only (RUO) solution for human leukocyte antigen (HLA) typing by next-generation sequencing (NGS). Last Updated: 2016.05.24 for trademark usage.
CANOGA PARK, Calif. April 7, 2015 (BUSINESS WIRE) --One Lambda, Inc., part of Thermo Fisher Scientific and leading producer of in vitro diagnostic products for the HLA transplant community, today announced the availability of the only FDA cleared and CE marked assay for detecting HNA-3, as well as HLA...
One Lambda, Inc. and GenoDive Pharma, Inc. Enter Exclusivity Agreement on Long-Range Primers for NGS
CANOGA PARK, Calif.--(BUSINESS WIRE)--One Lambda, Inc., part of Thermo Fisher Scientific, announced it has entered into an agreement with Japan-based GenoDive Pharma, Inc. for exclusive rights to their long-range primers and amplification conditions for human leukocyte antigen (HLA) locus-specific amplification. The agreement covers GenoDive’s primers and conditions for HLA A, B, C, DRB1, DRB345, DQA1, DQB1, DPA1 & DPB1 loci.
Newsletter | 2016.Q3Download Newsletter »
In This Issue:
- Bringing Real-Time PCR to the HLA Lab
- HLA Mismatched HSCT on the Rise: New Opportunities and New Barriers
- Communications Updates
- Upcoming Events, Tradeshows, and Workshops
Newsletter | 2016.Q1
In This Issue:
- Celebrating 30 Years of Education in HLA & Transplantation
- Product Updates
- New Product Releases
- Products in Development
- Going Green
Last Updated: 2016.05.24 (for trademark usage)